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Introduction
G protein-coupled receptors (GPCRs) represent a superfamily of cell surface receptors that regulate the activity of virtually all physiological functions. Characteristically, GPCRs are activated via binding of extracellular ligands which trigger conformational changes that allow the receptors to interact with and activate specific classes of heterotrimeric G proteins. The activated GPCRs are rapidly phosphorylated by G protein-coupled receptor kinases (GRKs; Pierce et al., 2002) . In most cases, the phosphorylated receptors bind to members of the arrestin protein family (arrestin-2 and -3; also known as β-arrestin-1 and -2), a process which interferes with receptor/G protein coupling and promotes GPCR internalization by targeting the receptors to clathrin-coated pits (Pierce et al., 2002) .
However, during the past decade, it has become increasingly clear that arrestin-2 and -3 can serve as adaptor proteins that transduce signals to multiple effector pathways (Rajagopal et al., 2010; Shukla et al., 2011) . Although some progress has been made in delineating the physiological functions of arrestin signaling pathways in various tissues, much remains to be learned about the in vivo physiological relevance of arrestin-mediated signaling. Importantly, such information is not only of theoretical interest, but could also be exploited for the development of novel classes of clinically useful drugs, including arrestin-biased agonists (Rajagopal et al. 2010; Shukla et al., 2011) .
To facilitate studies aimed at elucidating the physiological roles of arrestin-/2/3-dependent signaling, we set out to develop a designer GPCR that can recruit arrestins after binding of an exogenous ligand but that is no longer able to activate heterotrimeric G proteins. During the past few years, clozapine-N-oxide (CNO)-sensitive designer GPCRs have emerged as highly useful tools to dissect the in vivo roles of distinct G protein signaling pathways in specific cell types or tissues (Armbruster et al., 2007; Alexander et al., 2009; Guettier et al., 2009) . Structurally, these novel receptors (alternative names: designer receptors exclusively activated by designer drug (DREADDs) or second-generation receptors activated solely by synthetic ligand (RASSLs)) are muscarinic acetylcholine (ACh) receptors that contain two point mutations within the orthosteric binding pocket (Armbruster et al., 2007; Guettier et al., 2009) . As a result of these mutations, these This article has not been copyedited and formatted. The final version may differ from this version.
Molecular Pharmacology Fast Forward. Published on as DOI: 10.1124 at ASPET Journals on June 21, 2017 molpharm.aspetjournals.org Downloaded from MOL #80358 5 engineered receptors are unable to bind ACh, the endogenous muscarinic receptor ligand, but can be efficiently activated by CNO, an otherwise pharmacologically inert compound (Armbruster et al., 2007; Guettier et al., 2009) . CNO stimulation of DREADDs leads to the activation of distinct classes of heterotrimeric G proteins as well as the recruitment of arrestin-2 and -3 (Alvarez-Curto et al, 2011; Nakajima and Wess, unpublished results), in a fashion similar to that observed with endogenous GPCRs.
In the present study, we describe the generation and functional characterization of a novel M 3 muscarinic receptor-based DREADD containing a point mutation within the highly conserved DRY motif (Rq(R165L)) that lacks the ability to activate heterotrimeric G proteins (CNO treatment has no effect on the levels of conventional second messengers) but still retains the ability to recruit arrestin-2 and -3 in a CNO-dependent fashion. Rq(R165L)-dependent arrestin recruitment was functionally relevant, as demonstrated in ERK1/2 phosphorylation assays carried out with cultured HEK293T cells. Moreover, we found that CNO treatment of Rq(R165L)-expressing mouse insulinoma cells (MIN6 cells) stimulated insulin release in an arrestin-dependent fashion. This latter finding strongly supports the notion that this newly developed arrestin-biased DREADD represents a powerful new tool to study the physiological relevance of arrestin-dependent signal cascades in distinct tissues and cell types.
This article has not been copyedited and formatted. The final version may differ from this version. The coding sequence of Rq, an M 3 muscarinic receptor-based DREADD (Guettier et al., 2009), including an N-terminal hemagglutinin (HA) epitope tag, was amplified by PCR and inserted into the pcDNA3.1 (-) vector (Invitrogen, Carlsbad, CA) using the EcoRI and BamHI sites present in the polylinker. To generate a mutant version of Rq that was unable to couple to G proteins, we generated the Rq(R165L) construct containing the R165L point mutation, using the QuikChange site-directed mutagenesis kit (Invitrogen). For BRET studies, we generated plasmids (vector backbone: pcDNA3.1 (+)) coding for receptors in which the C-terminus of Rq or Rq(R165L) was fused to the coding sequence of Renilla luciferase 8 (Luc), yielding Rq-Luc and Rq(R165L)-Luc, respectively. These plasmids were obtained by using a strategy similar to the one we employed for generating M3-Luc (McMillin et al., 2011) . The correctness of all coding regions was verified by sequencing. Plasmids coding for rat GRK2 and Venus-tagged versions of arrestin-2 and -3 (V-arr2
and V-arr3, respectively) were kindly provided by Drs. Diaz Gimenez and Vsevolod Gurevich (Vanderbilt University) (Vishnivetskiy et al., 2011) . The mammalian expression plasmid coding for the wild-type M 3 muscarinic receptor (rat) has been desribed previously (Schöneberg et al., 1995) Cell Culture and Transfections. COS-7 cells and HEK293T cells were obtained from ATCC and cultured according to established protocols. MIN6 cells were a kind gift from Dr. Abner
Notkins (NIDCR, NIH) and were cultured as described (Ishihara et al., 1994) . COS-7 cells were transfected with plasmid DNA using Lipofectamine and Plus reagent (Invitrogen) according to the manufacturer's protocol. HEK293T and MIN6 cells were transfected as described below. Calcium Mobilization Assay. About 48 hr after transfection, cells were incubated with increasing concentrations of CNO, and changes in intracellular calcium levels were determined using FLIPR technology (Molecular Devices, Sunnyvale, CA). All measurements were carried out in 96-well plates, as described in detail previously McMillin et al., 2011) . CNO concentration-response curves were analyzed by using Prism 4.0 software.
BRET (Arrestin Recruitment) Studies. To monitor receptor-mediated arrestin-2 and -3 recruitment, we followed a protocol similar to that described by Klewe et al. (2008) . COS-7 cells were seeded onto 6-well plates at a density of 3 x 10 5 cells/well. About 24 hr after plating, cells (R165L)) and 120 pmol of arrestin-2, arrestin-3, or control siRNA. HEK293T cells were co-transfected using
GeneSilencer transfection reagent (Gene Therapy Systems, San Diego, CA), as previously described . MIN6 cells were co-transfected by employing Lipofectamine 2000 according to the manufacturer's protocol (Invitrogen). About 48 hr after transfection, cells were subjected to various assays (see below). We used the same arrestin siRNAs for HEK293T and MIN6 cells (human sequences described by Ahn et al., 2003) , since the corresponding mouse sequences differ at only one or two positions from the human siRNA sequences used.
Western Blotting (ERK1/2 Phosphorylation) Studies. HEK293T cells (~3 x 10 5 cells) were seeded into 12-well plates. About 24 hr later, cells were transfected (see previous paragraph) and incubated for another 24 hr. After a 5-6 hr starvation period in serum-free medium (Wei et al., 2003) , cells were treated with increasing concentrations of CNO for 2 min at 37 o C. Subsequently, the medium was removed, and 1 x Laemmli sample buffer was added to each well. Whole cell lysates were sonicated, resolved on Novex 10% Tris/glycine polyacrylamide gels (Invitrogen), and transferred to nitrocellulose membranes for immunoblotting. Phosphorylated ERK1/2 (pERK1/2), total ERK1/2, and arrestin-2 and -3 were detected via immunoblotting using the following primary antibodies: rabbit monoclonal anti-phospho-p44/42 (pERK, 1:2,000, Cell Signaling, Beverly, MA), rabbit polyclonal anti-p44/42 (total ERK1/2, 1:2,000, Cell Signaling), and mouse monoclonal antiarrestin-2 and -3 (1:2,000, BD Biosciences, San Jose, CA). HRP-labeled secondary antibodies (Cell Signaling) were used to detect the primary antibodies via chemiluminescence. Chemiluminescent
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Results and Discussion
Identification of an M 3 Receptor-based DREADD Unable to Couple to G q . We recently generated and characterized a rat M 3 muscarinic receptor-based DREADD that selectively couples to G proteins of the G q family (Rq; Guettier et al., 2009) . For the sake of simplicity, we refer to this receptor as 'Rq' throughout this manuscript.
Many studies have shown that mutational modification of an arginine residue that is highly conserved among class A GPCRs (R3.50 according to the Ballesteros-Weinstein GPCR numbering system; part of the highly conserved DRY motif) abolishes or drastically reduces agonist-dependent GPCR activation (http://www.gpcr.org/7tm/). Consistent with this observation, the recently solved crystal structure of an agonist-β 2 -adrenergic receptor-G s complex indicates that R3.50 contacts key regions of the G protein α-subunit that are predicted to be critical for productive receptor/G protein coupling (Rasmussen et al., 2011) .
We previously reported that a mutant M 3 receptor (rat) containing the R165L 3.50 point mutation virtually lost its ability to stimulate muscarinic agonist-induced inositol phosphate production in transfected COS-7 cells (Li et al., 2005) . In contrast, this mutation did not interfere with agonist and antagonist binding affinities and receptor expresssion levels (Li et al., 2005) . To examine whether this point mutation also disrupted signaling mediated by the Rq designer receptor, we generated the Rq(R165L) mutant receptor. In agreement with the data reported by Li et al. (2005) , CNO treatment of Rq(R165L)-expressing COS-7 cells had no significant effect on intracellular calcium levels ([Ca 2+ ] i ), as studied via FLIPR technology (Fig. 1A) . In contrast, CNO induced robust, concentration-dependent increases in [Ca 2+ ] i in Rq-expressing COS-7 cells (Fig. 1A) . The E max value for this response amounted to ~75% of the E max value observed with COS-7 cells expressing the wild-type M 3 muscarinic receptor (rat; Schöneberg et al., 1995) following stimulation with the full muscarinic agonist, oxotremorine-M (OXO-M; Fig. 1B (Fig. 1C) . We noted that CNO-dependent maximum BRET responses (BRET max ) were ~2.5-fold higher for the Rq-Luc/V-arr3 combination, as compared to the Rq-Luc/V-arr2 pair (BRET max values: Rq-Luc/V-arr2, 0.025 ± 0.003; Rq-Luc/V-arr3, 0.063 ± 0.007; p<0.01; n = 3).
Interestingly, Rq(R165L)-Luc-expressing cells yielded CNO-dependent BRET signals that
were qualitatively similar to those observed with Rq-Luc (Fig. 1C) . However, compared to Rq-Luc (see above), the interaction of Rq(R165L)-Luc with V-arr3 was characterized by a ~30% reduction in BRET max (0.045 ± 0.007; n = 3; p<0.05, as compared to Rq/V-arr3; Fig. 1C ). The Rq(R165L)-Luc/V-arr2 combination yielded a BRET max value (0.026 ± 0.005; n = 3) that was similar to the one observed with the Rq-Luc/V-arr2 pair (Fig. 1C) . CNO EC 50 values are given in the legend to Fig.   1C .
This article has not been copyedited and formatted. The final version may differ from this version. Fig. 2A) . The E max value for this latter response amounted to ~65% of the E max value observed with OXO-M-stimulated HEK293T cells expressing the wild-type M 3 receptor (Fig. 2B ).
Since the Rq(R165L) receptor retained the ability to recruit arrestins in BRET assays, we next examined whether this receptor was able to stimulate ERK1/2 phosphorylation in HEK293T cells.
Specifically, we transfected HEK293T cells with plasmid DNA coding for Rq or Rq(R165L), together with either arrestin-3 siRNA or negative control siRNA. Under these experimental conditions, the use of arrestin-3 siRNA reduced arrestin-3 protein expression by ~70% (Fig. 2D) . Moreover, incubation of Rq(R165L)-expressing MIN6 cells with CNO did not lead to any detectable changes in cAMP levels (Fig. 3C ).
To study the potential role of arrestin signaling in regulating insulin secretion, we transfected ( Fig. 4A, B) . However, treatment of both Rq-and Rq(R165L)-expressing cells with arrestin-2 or -3 siRNA led to significant reductions in insulin secretion (Fig. 4A-C) . Arrestin-2 or -3 knockdown reduced but did not completely prevent insulin secretion following CNO treatment of Rq(R165L)-expressing cells. One possible explanation for this observation is that treatment of MIN6 cells with arrestin-2/3 siRNA lowered but did not abolish arrestin-2/3 protein expression (~50-70% reduction in arrestin-2/3 expression; Fig. 4D ). In agreement with our findings, several recent studies suggest that activation of arrestin-dependent signaling pathways can promote insulin release from pancreatic β-cells or insulinoma cells (Sonoda et al., 2008; Kong et al., 2010 ).
In conclusion, we developed a new CNO-sensitive designer GPCR (Rq(R165L)) that fails to activate G proteins but is able to recruit arrestins and promote arrestin-dependent signaling.
Importantly, when expressed in a β-cell line, activation of Rq(R165L) resulted in arrestindependent insulin release, highlighting the potential usefulness of this newly developed, arrestinbiased DREADD to study the physiological roles of arrestin signaling pathways. It should be noted that arrestin-biased GPCRs have been described previously (Wei et al., 2003; Shenoy et al., 2006) . shows pooled data from three independent experiments (means ± SEM). All assays were carried out in duplicate. The CNO EC 50 value at the Rq receptor was 28.2 ± 7.7 nM, and the OXO-M EC 50
value at the wild-type M 3 receptor was 2.33 ± 0.31 nM, respectively (means ± SEM; n = 3). AU, led to a strong reduction in arr3 protein expression (note that the arrestin antibody used recognized both arr2 and arr3). Panel (E) provides a summary of pERK1/2 protein levels (pooled data). In each individual experiment, band intensities in the absence of CNO were set equal to 1 (ND, no drug).
Each bar represents the mean ± SEM from three or four independent experiments. *p<0.05, **p<0.01, and ***p<0.001 vs. the corresponding control response. experiments. All assays were carried out in duplicate. The CNO EC 50 value at the Rq receptor was 28.2 ± 7.7 nM, and the OXO-M EC 50 value at the wild-type M 3 receptor was 1.00 ± 0.12 μM, respectively (means ± SEM; n = 3). AU, arbitrary units. B, cAMP assay. MIN6 cells transiently expressing the Rq(R165L) construct were incubated with increasing concentrations of forskolin or CNO. cAMP concentrations were measured in cell lysates by using a FRET-based cAMP kit (for details, see Materials and Methods). Data are given as means ± SEM of three independent experiments, each carried out in duplicate. independent experiments. The panels shows relative insulin responses at two different CNO concentrations (CTL siRNA = 100%). *p<0.05, **p<0.01, vs. the corresponding control response.
D, Arrestin levels were monitored via Western blotting using an anti-arrestin antibody that recognized both arr2 and arr3. Cells were incubated with increasing concentrations of CNO for 60 min at 37 o C in the presence of 16.7 mM glucose, and insulin secretin into the medium was determined as described under Materials and Methods. CNO EC 50 (in μM) and E max values (in ng insulin/ml) were as follows (means ± SEM, n = 3): Rq + CTL siRNA: EC 50 = 0.55 ± 0.33, E max = 43.5 ± 3.5; Rq + arr2 siRNA: EC 50 = 4.60 ± 0.96, E max = 28.1 ± 1.5; Rq + arr3 siRNA: EC 50 = 2.98 ± 0.84, E max = 39.9 ± 2.1; Rq(R165L) + CTL siRNA: EC 50 = 2.14 ± 0.40, E max = 40.3 ± 3.82;
Rq(R165L) + arr2 siRNA: EC 50 = 1.16 ± 0.88, E max = 27.2 ± 0.80; Rq(R165L) + arr3 siRNA: EC 50 = 1.33 ± 0.32, E max = 26.9 ± 2.93.
